Best Probiotics After Antibiotics: A Science-Backed Recovery Guide
Evidence-based strategies for restoring gut health and preventing antibiotic-associated diarrhea with clinically studied probiotic strains
Antibiotics save lives—but they don't discriminate between harmful pathogens and the beneficial bacteria that keep your digestive system running smoothly. Research shows that a single course of antibiotics can reduce gut microbiome diversity by over 66% and leave lasting imprints on microbial communities for months or even years.[1]
The consequences extend beyond temporary digestive upset. Antibiotic-associated diarrhea (AAD) affects 5-35% of patients, depending on the antibiotic prescribed.[2] More concerning, some beneficial species—particularly Bifidobacterium populations—may remain depleted six months after treatment ends.[1] This is where targeted probiotic supplementation can make a significant difference.
Meta-analyses involving thousands of participants consistently demonstrate that specific probiotic strains can reduce AAD risk by 37-51% when taken during and after antibiotic therapy.[3][4] But not all probiotics are equally effective—strain selection, dosage, and timing all influence outcomes. This guide examines the clinical evidence for specific strains, explores optimal protocols, and addresses the nuanced question of which probiotics for antibiotic recovery actually work.
Whether you're currently on antibiotics, recently finished a course, or simply want to understand how to support gut health that may have been compromised, this evidence-based resource will help you make informed decisions about probiotic supplementation.
Key Takeaways
- Probiotics reduce antibiotic-associated diarrhea by 37-51% according to multiple meta-analyses involving over 11,000 participants—with multistrain formulations showing superior protection (RR=0.40) compared to single strains (RR=0.60).[3][5]
- Lactobacillus rhamnosus GG ranks as the most effective single strain for AAD prevention, reducing risk from 22.4% to 12.3% in meta-analysis (RR=0.49) with the highest probability of being ranked best for both effectiveness and tolerance.[6][7]
- Bacillus clausii spore-forming probiotics demonstrate unique antibiotic resistance, reducing AAD severity by 12-fold in clinical trials while surviving concurrent antibiotic treatment—making them particularly valuable during active antibiotic therapy.[8]
- Higher doses correlate with better outcomes—clinical evidence suggests 5-40 billion CFU daily provides significant protection, with timing during antibiotic therapy (not just after) being critical for maximum benefit.[4]
- Gut microbiome recovery takes 1.5-6 months after antibiotic exposure, with some beneficial species remaining undetectable at 180 days in certain individuals—supporting the case for extended probiotic supplementation.[1]
- Bifidobacterium species are particularly vulnerable to antibiotic depletion and benefit from targeted restoration through supplementation with strains like B. bifidum, B. longum, and B. lactis.[9]
How Antibiotics Affect Your Gut Microbiome
Understanding the scope of antibiotic-induced disruption helps explain why targeted probiotic intervention matters. Antibiotics don't selectively target pathogens—they affect broad categories of bacteria based on their mechanisms of action, often devastating beneficial populations in the process.
The Collateral Damage of Antibiotic Therapy
A landmark study tracking healthy adults through antibiotic exposure found dramatic and persistent changes to the gut ecosystem. Within days of starting a broad-spectrum antibiotic regimen, researchers observed blooms of opportunistic species like Enterococcus faecalis and Fusobacterium nucleatum, alongside significant depletion of beneficial Bifidobacterium species and butyrate-producing bacteria essential for colon health.[1]
The gut microbiota recovered to near-baseline composition within approximately 1.5 months for most subjects. However, nine common species present in all subjects before treatment remained undetectable in most participants even 180 days later—highlighting how certain beneficial populations may be permanently altered by antibiotic exposure.
Rebuilding your gut's ability to produce short-chain fatty acids is a key part of post-antibiotic recovery—our guide on increasing butyrate and SCFAs covers effective strategies.
Why Bifidobacterium Depletion Matters
Bifidobacterium species are among the most vulnerable to antibiotic disruption and among the most important for gut health. These bacteria produce short-chain fatty acids that nourish colon cells, support immune function, and maintain the gut barrier. Research shows B. longum and B. adolescentis populations often show incomplete recovery even weeks after antibiotic therapy ends.[9] Understanding signs of Bifidobacterium deficiency can help you recognize when supplementation may be particularly beneficial.
Types of Antibiotics and Their Impact
Not all antibiotics affect the microbiome equally. Broad-spectrum antibiotics targeting anaerobic bacteria—including cephalosporins, aminopenicillins, and fluoroquinolones—generally cause more extensive disruption.[2] The risk of antibiotic-associated diarrhea varies accordingly, ranging from 2-15% for narrower-spectrum agents to significantly higher rates for broader therapies.
Antibiotic-Associated Diarrhea Risk Factors
| Factor | Impact on AAD Risk |
|---|---|
| Broad-spectrum antibiotics | Higher risk (cephalosporins, fluoroquinolones, clindamycin) |
| Treatment duration | Longer courses increase risk |
| Age | Higher risk in elderly and very young |
| Hospitalization | Increased exposure to resistant pathogens |
| Previous AAD history | Elevated recurrence risk |
| Concurrent probiotic use | 37-51% risk reduction[3] |
The Evidence for Probiotics During Antibiotic Therapy
The scientific case for probiotic co-administration with antibiotics has strengthened considerably over the past decade. Multiple large-scale meta-analyses now support their use for preventing antibiotic-associated diarrhea, though the evidence emphasizes that strain selection matters enormously.
Meta-Analysis Evidence: 42 Studies, 11,305 Participants
A systematic review published in BMJ Open Gastroenterology pooled data from 42 randomized controlled trials. The analysis found that co-administration of probiotics with antibiotics reduced AAD risk by 37% (RR=0.63, 95% CI: 0.54-0.73). This protective effect remained significant across subgroups regardless of antibiotic type, treatment duration, or reason for antibiotic prescription.[3]
A more recent 2024 meta-analysis of 15 trials with 7,427 participants found even stronger effects, with probiotics reducing AAD incidence by 40% overall. Crucially, this analysis revealed significant differences based on probiotic formulation: multistrain probiotics showed superior protection (RR=0.40) compared to dual-strain (RR=0.90) and single-strain (RR=0.60) formulations.[5]
What the Evidence Tells Us
Several consistent patterns emerge from the clinical literature:
Timing matters: Starting probiotics early—ideally with the first antibiotic dose—provides better protection than waiting until after treatment ends. The protective effect remains significant when probiotics are started during antibiotic therapy.[4]
Dose-response relationship exists: Higher doses (5-40 billion CFU daily) show more consistent benefits than lower doses. This aligns with the understanding that sufficient bacterial populations must survive gastric transit to colonize the intestine effectively.[10]
Strain specificity is critical: Not all probiotics work equally well. Lactobacillus rhamnosus GG and certain Bacillus species consistently demonstrate efficacy, while evidence for other strains remains mixed or insufficient.
26-Strain Probiotic Support for Antibiotic Recovery
MicroBiome Restore delivers 15 billion CFU across 26 clinically studied strains—including L. rhamnosus, multiple Bifidobacterium species, and spore-forming Bacillus strains that survive antibiotic exposure. Our filler-free formula is specifically designed for comprehensive gut support.
Best Probiotic Strains for Antibiotic Recovery
Research has identified specific strains with strong evidence for preventing antibiotic-associated complications and supporting microbiome recovery. The following strains represent the best-documented options based on randomized controlled trials and meta-analyses.
Lactobacillus rhamnosus
Strain Spotlight: Lactobacillus rhamnosus GG
The evidence: A network meta-analysis comparing 10 different probiotic interventions across 51 studies (9,569 participants) ranked L. rhamnosus GG as having the highest probability of being best for both AAD prevention effectiveness and tolerance.[7]
Clinical outcomes: Treatment with LGG reduced AAD risk from 22.4% to 12.3% compared to placebo (RR=0.49, 95% CI: 0.29-0.83). The strain showed particular efficacy in children and in adults receiving antibiotics for Helicobacter pylori eradication (RR=0.26).[6]
Mechanisms: L. rhamnosus enhances intestinal epithelium survival, preserves cytoskeletal integrity, and secretes lectin-like proteins that resist pathogenic biofilms—explaining its robust clinical performance.
Bifidobacterium Species
Multiple Bifidobacterium species contribute to microbiome recovery and AAD prevention, making them essential components of any comprehensive antibiotic recovery protocol.
Bifidobacterium bifidum: Research demonstrates that B. bifidum supplementation can suppress gut inflammation caused by repeated antibiotic disturbance. Notably, while it doesn't fully restore microbiome diversity on its own, B. bifidum increases populations of beneficial Bacteroidales S24-7 family members associated with short-chain fatty acid production.[9]
Bifidobacterium lactis: Clinical trials confirm efficacy in reducing diarrhea duration. A randomized controlled study found B. lactis BLa80 significantly shortened total diarrhea duration (122.6 vs. 148.4 hours, p<0.001) while improving gut microbiome composition.[11] For more on this strain, see our guide to Bifidobacterium lactis benefits.
Bifidobacterium longum: One of the most abundant species in the healthy infant gut, B. longum demonstrates exceptional colonization ability—persisting in the gut of 30% of trial subjects for six months following a single oral administration. This persistence makes it particularly valuable for long-term microbiome support.[12] Learn more in our article on Bifidobacterium longum.
Bacillus Species: The Antibiotic-Resistant Advantage
Spore-forming Bacillus species offer a unique advantage during active antibiotic therapy: their spores can survive exposure to many antibiotics, allowing them to provide protection even when taken concurrently with antibiotic medications.
Strain Spotlight: Bacillus clausii
The evidence: A randomized controlled trial demonstrated that B. clausii reduced AAD severity score by 12.4-fold in children and 2.3-fold in adults compared to placebo. Patients achieved normal stool consistency significantly faster with probiotic treatment.[8]
Antibiotic resistance: B. clausii exhibits resistance to multiple antibiotic classes, ensuring the probiotic remains viable during concurrent antibiotic treatment. Two randomized, double-blind, placebo-controlled trials confirmed significantly lower AAD incidence in adults receiving B. clausii during H. pylori eradication therapy (10% vs. 30% diarrhea risk, RR=0.33).[13]
Spore stability: As a spore-former, B. clausii survives gastric acid, bile salts, and shelf storage without refrigeration—practical advantages for supplementation protocols.
Bacillus coagulans: Another spore-forming species with documented benefits for antibiotic recovery. A high-dose multistrain trial including B. coagulans alongside Lactobacillus and Bifidobacterium species reduced AAD risk by 64% compared to placebo.[14]
Additional Evidence-Based Strains
Lactobacillus acidophilus: Multiple trials demonstrate efficacy for AAD prevention. A multispecies probiotic containing L. acidophilus alongside Bifidobacterium strains reduced C. difficile-associated diarrhea duration in patients undergoing antibiotic treatment.[15] Those experiencing signs of Lactobacillus deficiency may benefit particularly from supplementation during antibiotic therapy.
Lactobacillus plantarum: This versatile strain demonstrates improved gastrointestinal survival when combined with prebiotic fibers, and contributes to butyrate production—the primary fuel for colon cells. Learn more about the health benefits of Lactobacillus plantarum.
Lactobacillus casei: Network meta-analysis found L. casei to be the most efficacious choice specifically for severe Clostridioides difficile-related cases (OR=0.04), though with moderate tolerance ratings.[7]
The Multi-Strain Advantage
While individual strains like L. rhamnosus GG show strong standalone efficacy, accumulating evidence suggests that multi-strain formulations may provide superior protection for antibiotic recovery. This makes intuitive sense—antibiotics disrupt a complex ecosystem of hundreds of species, so restoration likely requires diverse bacterial support.
Meta-Analysis: Multi-Strain vs. Single-Strain Performance
Analysis of 15 trials with 7,427 participants revealed significant differences based on probiotic composition. Multistrain probiotics showed the strongest protection against AAD (RR=0.40), substantially outperforming both dual-strain (RR=0.90) and single-strain (RR=0.60) formulations. The researchers concluded that multistrain preparations enhance microbial diversity, which is particularly beneficial for counteracting antibiotic effects in the gut lumen.[5]
Why Diversity Matters
Different probiotic species occupy different ecological niches and provide complementary benefits:
Lactobacillus species primarily colonize the small intestine and upper colon, produce lactic acid, and compete with pathogens for adhesion sites.
Bifidobacterium species predominate in the large intestine, produce acetate and lactate, and are particularly important for immune modulation and barrier function.
Bacillus species survive antibiotic exposure as spores, produce antimicrobial compounds, and can support recovery even during active antibiotic treatment.
A systematic review of multi-strain probiotics for H. pylori eradication found that four different multi-strain formulations significantly improved eradication rates, five prevented adverse reactions, and three specifically reduced AAD—demonstrating that well-designed combinations can address multiple clinical endpoints simultaneously.[16]
For a deeper exploration of why strain diversity matters, see our comprehensive guide on single vs. multi-strain probiotics.
Comprehensive Multi-Strain Support
MicroBiome Restore includes 26 distinct probiotic strains across Lactobacillus, Bifidobacterium, Bacillus, and supporting species—providing the diversity shown in research to optimize antibiotic recovery outcomes. This includes L. rhamnosus, L. acidophilus, L. plantarum, B. bifidum, B. longum, B. lactis, B. clausii, B. coagulans, and many more clinically studied strains.
Timing and Dosage Protocol
When and how you take probiotics during antibiotic therapy significantly affects their efficacy. Research provides clear guidance on optimizing your supplementation protocol.
When to Start Probiotics
The clinical consensus supports starting probiotic supplementation as early as possible—ideally with the first dose of antibiotics. A meta-analysis specifically examined timing effects and found that probiotics initiated during antibiotic therapy provided significant protection, with the protective effect maintained regardless of when during treatment probiotics were started.[4]
Optimal Timing Strategy
During antibiotic treatment: Take probiotics at least 2-3 hours apart from antibiotic doses. This separation allows probiotic bacteria to survive initial exposure, though spore-forming strains like Bacillus clausii can be taken closer to antibiotic timing.
After antibiotic completion: Continue probiotic supplementation for at least 1-2 weeks after finishing antibiotics. Some research suggests extending supplementation for 4 weeks or longer to support complete microbiome recovery.
Dosage Considerations
Clinical evidence supports higher doses for AAD prevention. Overview analyses of pediatric studies suggest that high-dose probiotics (5-40 billion CFU daily) provide significant protection.[10] A recent high-dose multistrain trial using approximately 30 billion CFU daily achieved a 64% reduction in AAD risk—one of the strongest effects reported in the literature.[14]
Evidence-Based Dosage Guidelines
| Population | Suggested Daily Dose | Evidence Level |
|---|---|---|
| Adults | 10-30 billion CFU | Strong (multiple meta-analyses) |
| Children | 5-10 billion CFU | Moderate-Strong |
| High-risk patients | 30+ billion CFU | Moderate (emerging evidence) |
Note: These are general guidelines based on clinical trial protocols. Individual needs may vary. Consult with a healthcare provider for personalized recommendations.
For guidance on optimizing probiotic absorption, see our detailed guide on the best time to take probiotics.
Microbiome Recovery Timeline
Understanding how long gut recovery takes helps set realistic expectations and guides the duration of probiotic supplementation. Research provides increasingly detailed pictures of the recovery process.
Typical Microbiome Recovery Phases
Days 1-7: Acute disruption phase. Microbiome diversity drops dramatically. Opportunistic pathogens may bloom. AAD risk is highest during this period and immediately following.
Weeks 2-6: Initial recovery phase. Bacterial diversity begins rebuilding. Most individuals see gradual return toward baseline composition. This is when many beneficial species begin recolonizing.
Months 1.5-6: Extended recovery phase. Gut microbiota recovers to near-baseline composition for most people within 1.5 months. However, some species may remain depleted much longer.[1]
Individual Variation in Recovery
Recovery timelines vary significantly between individuals. Research tracking healthy adults found that while the gut microbiome generally recovered within 1.5 months, nine common species present in all subjects before antibiotic treatment remained undetectable in most subjects at 180 days.[1]
Factors influencing recovery speed include:
Pre-existing microbiome diversity: Individuals with higher baseline diversity tend to recover faster and more completely.
Antibiotic type and duration: Broader-spectrum antibiotics and longer courses typically cause more persistent disruption.
Diet: High-fiber diets support faster recovery by providing substrate for beneficial bacteria to ferment.
Previous antibiotic exposure: Multiple prior antibiotic courses may impair recovery capacity.
Supporting Long-Term Recovery
Beyond probiotic supplementation, dietary strategies can accelerate microbiome restoration. Prebiotic fibers—found in foods like Jerusalem artichoke, garlic, onions, and asparagus—provide fuel for beneficial bacteria to thrive. Research shows that combining prebiotics and probiotics (synbiotic approach) may enhance recovery outcomes compared to either alone.
Support Your Microbiome Recovery
MicroBiome Restore combines 26 probiotic strains with 9 organic prebiotic ingredients in a synbiotic formula designed for comprehensive gut support. Our filler-free formula delivers 15 billion CFU per serving to help restore what antibiotics take away.
Frequently Asked Questions
Can I take probiotics at the same time as antibiotics?
Yes, but spacing them 2-3 hours apart is generally recommended to maximize probiotic survival. Spore-forming probiotics like Bacillus clausii are more antibiotic-resistant and can be taken closer to antibiotic doses. Clinical evidence strongly supports starting probiotics during antibiotic treatment rather than waiting until after, as the protective effects against AAD are most needed during active therapy.[4]
How long should I take probiotics after antibiotics?
At minimum, continue probiotic supplementation for 1-2 weeks after completing antibiotics. Given that research shows microbiome recovery can take 1.5-6 months, extending supplementation for several weeks to months may provide additional benefit, particularly for individuals with compromised gut health or those who've undergone multiple antibiotic courses.[1]
Do probiotics interfere with antibiotic effectiveness?
No. Probiotics do not reduce antibiotic effectiveness against the infection being treated. Clinical trials consistently show that probiotic co-administration maintains antibiotic efficacy while reducing side effects. In H. pylori eradication studies, multi-strain probiotics actually improved eradication rates while reducing adverse events.[16]
Which probiotic is best for antibiotic-associated diarrhea?
Lactobacillus rhamnosus GG has the strongest evidence for AAD prevention as a single strain. However, multi-strain formulations combining multiple Lactobacillus, Bifidobacterium, and Bacillus species show superior protection in meta-analyses (RR=0.40 vs. 0.60 for single strains).[5][7]
Are there any risks to taking probiotics during antibiotic treatment?
Probiotics are generally safe for most individuals. Meta-analyses consistently show no increased adverse events in probiotic groups compared to placebo.[3] However, severely immunocompromised individuals should consult healthcare providers before supplementation, as rare cases of probiotic-related bacteremia have been reported in this population.
Does the CFU count matter for antibiotic recovery?
Yes. Higher doses (5-40 billion CFU daily) show more consistent benefits in clinical trials. A dose-response relationship exists, with higher potency formulations generally providing stronger protection. However, strain quality and diversity may be equally important as raw CFU counts.[10]
Can probiotics help if I've already developed diarrhea from antibiotics?
Research supports probiotic use for both prevention and treatment of AAD. Bacillus clausii specifically demonstrated efficacy in reducing diarrhea severity and duration in individuals already experiencing AAD, shortening time to normal stool consistency.[8]
Should I choose refrigerated or shelf-stable probiotics?
Both can be effective if properly manufactured. Spore-forming probiotics (Bacillus species) are inherently shelf-stable. For non-spore-forming strains like Lactobacillus and Bifidobacterium, quality manufacturing and proper storage are more important than refrigeration status. Look for products with verified CFU counts at expiration, not just at manufacture.
Conclusion: Evidence-Based Recovery Support
The evidence is clear: targeted probiotic supplementation during and after antibiotic therapy significantly reduces the risk of antibiotic-associated diarrhea while supporting faster microbiome recovery. Meta-analyses involving thousands of participants consistently demonstrate 37-51% risk reductions, with multi-strain formulations showing the strongest protective effects.
Key principles for optimizing your antibiotic recovery protocol:
Start early: Begin probiotic supplementation with your first antibiotic dose, spacing them 2-3 hours apart.
Choose evidence-based strains: Lactobacillus rhamnosus, Bifidobacterium species, and spore-forming Bacillus strains have the strongest clinical support.
Consider multi-strain formulations: Research suggests multi-strain products outperform single-strain supplements for AAD prevention.
Use adequate doses: Clinical evidence supports 10-30 billion CFU daily for adults.
Continue after treatment: Extend supplementation for at least 1-2 weeks after completing antibiotics, potentially longer for optimal recovery.
For comprehensive guidance on building and maintaining a healthy gut microbiome, explore our complete guide to MicroBiome Restore or learn more about the top probiotic strains for gut health.
References
- Palleja, A., Mikkelsen, K. H., Forslund, S. K., Kashani, A., Allin, K. H., Nielsen, T., ... & Pedersen, O. (2018). Recovery of gut microbiota of healthy adults following antibiotic exposure. Nature Microbiology, 3(11), 1255-1265. https://doi.org/10.1038/s41564-018-0257-9
- Bartlett, J. G. (2002). Clinical practice. Antibiotic-associated diarrhea. New England Journal of Medicine, 346(5), 334-339. https://doi.org/10.1056/NEJMcp011603
- Goodman, C., Keating, G., Georgousopoulou, E., Hespe, C., & Levett, K. (2021). Probiotics for the prevention of antibiotic-associated diarrhoea: a systematic review and meta-analysis. BMJ Open Gastroenterology, 8(1), e000630. https://doi.org/10.1136/bmjgast-2021-000630
- Guo, Q., Goldenberg, J. Z., Humphrey, C., El Dib, R., & Johnston, B. C. (2019). Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database of Systematic Reviews, 4(4), CD004827. https://doi.org/10.1002/14651858.CD004827.pub5
- Wanyama, H., Akhtar, T. S., & Abbas, S. (2024). Probiotic use reduces the incidence of antibiotic-associated diarrhea among adult patients: a meta-analysis. Gastroenterology Review, 19(1), 58-68. https://doi.org/10.5114/pg.2024.137183
- Szajewska, H., & Kołodziej, M. (2015). Systematic review with meta-analysis: Lactobacillus rhamnosus GG in the prevention of antibiotic-associated diarrhoea in children and adults. Alimentary Pharmacology & Therapeutics, 42(10), 1149-1157. https://doi.org/10.1111/apt.13404
- Guo, Q., Goldenberg, J. Z., Humphrey, C., El Dib, R., & Johnston, B. C. (2018). Comparative efficacy and tolerability of probiotics for antibiotic-associated diarrhea: Systematic review with network meta-analysis. United European Gastroenterology Journal, 6(2), 169-180. https://doi.org/10.1177/2050640617736987
- Maity, C., & Gupta, A. K. (2021). Therapeutic efficacy of probiotic Alkalihalobacillus clausii 088AE in antibiotic-associated diarrhea: A randomized controlled trial. Heliyon, 7(9), e08078. https://doi.org/10.1016/j.heliyon.2021.e08078
- Suez, J., Zmora, N., Zilberman-Schapira, G., Mor, U., Dori-Bachash, M., Bashiardes, S., ... & Elinav, E. (2018). Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT. Cell, 174(6), 1406-1423. https://doi.org/10.1016/j.cell.2018.08.047
- Liu, J., Lv, W., Shi, J., Zhang, L., & Chen, Y. (2023). Overview of systematic reviews of probiotics in the prevention and treatment of antibiotic-associated diarrhea in children. Frontiers in Pharmacology, 14, 1153070. https://doi.org/10.3389/fphar.2023.1153070
- Sun, H., Liu, C., Zhang, Y., Wang, Y., & Chen, Q. (2024). Adjudicative efficacy of Bifidobacterium animalis subsp. lactis BLa80 in treating acute diarrhea in children: a randomized, double-blinded, placebo-controlled study. European Journal of Clinical Nutrition, 78(5), 430-438. https://doi.org/10.1038/s41430-024-01428-6
- Groeger, D., Schiavi, E., Grant, R., Paber, L., O'Connor, R., Wall, R., ... & O'Mahony, L. (2023). Efficacy of Bifidobacterium longum alone or in multi-strain probiotic formulations during early life and beyond. Gut Microbes, 15(1), 2186098. https://doi.org/10.1080/19490976.2023.2186098
- Ianiro, G., Rizzatti, G., Napoli, M., Matteo, M. V., Rinaldo, F., Leonardi, E., ... & Gasbarrini, A. (2022). Bacillus clausii for Gastrointestinal Disorders: A Narrative Literature Review. Advances in Therapy, 39(11), 4854-4874. https://doi.org/10.1007/s12325-022-02285-0
- Hodzhev, V., Dzhambazov, K., Sapundziev, N., Encheva, M., Todorov, S., Youroukova, V., ... & Hadjiev, V. (2024). High-dose Probiotic Mix of Lactobacillus spp., Bifidobacterium spp., Bacillus coagulans, and Saccharomyces boulardii to Prevent Antibiotic-associated Diarrhea in Adults: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial (SPAADA). Open Forum Infectious Diseases, 11(11), ofae615. https://doi.org/10.1093/ofid/ofae615
- Barker, A. K., Duster, M., Valentine, S., Hess, T., Archbald-Pannone, L., Guerrant, R., & Safdar, N. (2018). Oral probiotic combination of Lactobacillus and Bifidobacterium alters the gastrointestinal microbiota during antibiotic treatment for Clostridium difficile infection. PLOS ONE, 13(9), e0204253. https://doi.org/10.1371/journal.pone.0204253
- McFarland, L. V., Huang, Y., Wang, L., & Malfertheiner, P. (2016). Systematic review and meta-analysis: Multi-strain probiotics as adjunct therapy for Helicobacter pylori eradication and prevention of adverse events. United European Gastroenterology Journal, 4(4), 546-561. https://doi.org/10.1177/2050640615617358
- Lukasik, J., Szajewska, H., & Szajewska, H. (2022). Multispecies Probiotic for the Prevention of Antibiotic-Associated Diarrhea in Children: A Randomized Clinical Trial. JAMA Pediatrics, 176(9), 860-866. https://doi.org/10.1001/jamapediatrics.2022.1973
- Dang, H. T., Tran, D. M., Phung, T. T. B., Bui, A. T. P., Vu, Y. H., Luong, M. T., ... & Nguyen, A. H. (2024). Promising clinical and immunological efficacy of Bacillus clausii spore probiotics for supportive treatment of persistent diarrhea in children. Scientific Reports, 14(1), 6422. https://doi.org/10.1038/s41598-024-56627-9
- Hempel, S., Newberry, S. J., Maher, A. R., Wang, Z., Miles, J. N., Shanman, R., ... & Shekelle, P. G. (2012). Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA, 307(18), 1959-1969. https://doi.org/10.1001/jama.2012.3507
- Sánchez, B., Delgado, S., Blanco-Míguez, A., Lourenço, A., Gueimonde, M., & Margolles, A. (2017). Probiotics, gut microbiota, and their influence on host health and disease. Molecular Nutrition & Food Research, 61(1), 1600240. https://doi.org/10.1002/mnfr.201600240
'%3e%3cg%20id='Final-Copy-2_2_'%20transform='translate(1275.000000,%20200.000000)'%3e%3cpath%20class='st0'%20d='M7.4,12.8h6.8l3.1-11.6H7.4C4.2,1.2,1.6,3.8,1.6,7S4.2,12.8,7.4,12.8z'/%3e%3c/g%3e%3c/g%3e%3c/g%3e%3cg%20id='final---dec.11-2020'%3e%3cg%20id='_x30_208-our-toggle'%20transform='translate(-1275.000000,%20-200.000000)'%3e%3cg%20id='Final-Copy-2'%20transform='translate(1275.000000,%20200.000000)'%3e%3cpath%20class='st1'%20d='M22.6,0H7.4c-3.9,0-7,3.1-7,7s3.1,7,7,7h15.2c3.9,0,7-3.1,7-7S26.4,0,22.6,0z%20M1.6,7c0-3.2,2.6-5.8,5.8-5.8%20h9.9l-3.1,11.6H7.4C4.2,12.8,1.6,10.2,1.6,7z'/%3e%3cpath%20id='x'%20class='st2'%20d='M24.6,4c0.2,0.2,0.2,0.6,0,0.8l0,0L22.5,7l2.2,2.2c0.2,0.2,0.2,0.6,0,0.8c-0.2,0.2-0.6,0.2-0.8,0%20l0,0l-2.2-2.2L19.5,10c-0.2,0.2-0.6,0.2-0.8,0c-0.2-0.2-0.2-0.6,0-0.8l0,0L20.8,7l-2.2-2.2c-0.2-0.2-0.2-0.6,0-0.8%20c0.2-0.2,0.6-0.2,0.8,0l0,0l2.2,2.2L23.8,4C24,3.8,24.4,3.8,24.6,4z'/%3e%3cpath%20id='y'%20class='st3'%20d='M12.7,4.1c0.2,0.2,0.3,0.6,0.1,0.8l0,0L8.6,9.8C8.5,9.9,8.4,10,8.3,10c-0.2,0.1-0.5,0.1-0.7-0.1l0,0%20L5.4,7.7c-0.2-0.2-0.2-0.6,0-0.8c0.2-0.2,0.6-0.2,0.8,0l0,0L8,8.6l3.8-4.5C12,3.9,12.4,3.9,12.7,4.1z'/%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Your Privacy Choices
Share and get 15% off!
Simply share this product on one of the following social networks and you will unlock 15% off!